| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
- Fosfructose acts as a metabolic modulator targeting enzymes involved in glycolysis (e.g., phosphofructokinase), enhancing ATP production and promoting cellular energy metabolism.
|
|---|---|
| ln Vitro |
- Fosfructose increases intracellular ATP and phosphocreatine levels in ischemic cells by activating glycolytic enzymes (e.g., phosphofructokinase and pyruvate kinase), thereby improving energy supply under hypoxic conditions. [1]
|
| ln Vivo |
- In animal models, Fosfructose reduces ischemic myocardial damage and improves cardiac function by maintaining energy metabolism during hypoxia. It also promotes potassium ion influx into cells, stabilizing membrane potential and protecting against cellular injury. [1]
|
| Enzyme Assay |
- Glycolytic Enzyme Activity Analysis: Cell lysates or tissue homogenates were incubated with Fosfructose under physiological conditions. Enzyme activities (e.g., phosphofructokinase) were measured by monitoring the conversion of substrates (e.g., fructose-6-phosphate) to products (e.g., fructose-1,6-bisphosphate) using spectrophotometric methods. [1]
|
| Cell Assay |
- Cell Viability and Energy Metabolism Assessment: Cells exposed to hypoxia or ischemia were treated with Fosfructose. ATP levels were quantified using luciferase-based assays, and cell viability was evaluated via MTT or LDH release assays. The drug’s effects on potassium ion influx were measured using fluorescent probes or patch-clamp techniques. [1]
|
| Animal Protocol |
- Ischemic Injury Model: Animals (e.g., mice or rabbits) were subjected to myocardial ischemia-reperfusion injury. Fosfructose was administered intravenously at specified doses (e.g., 250 mg/kg) immediately after ischemia induction. Cardiac function was assessed via echocardiography, and tissue samples were analyzed for ATP content and histological damage. [1]
|
| ADME/Pharmacokinetics |
Distribution: Phosphofructosyl is rapidly distributed to tissues including the heart and brain after intravenous injection. [1] - Elimination: The drug is hydrolyzed into fructose and inorganic phosphate, which are excreted by the kidneys. The plasma half-life is approximately 10-15 minutes. [1] #### Toxicity/Toxicokinetics - Acute toxicity: The median lethal dose (LD50) for mice and rabbits is 5.0 g/kg and 5.8 g/kg, respectively (administered via high-rate intravenous infusion). Toxicity is attributed to phosphate overload caused by drug hydrolysis. [1] - Safety: Clinical trials have reported no significant adverse reactions at therapeutic doses and minimal drug interactions. [1]
|
| Toxicity/Toxicokinetics |
Acute toxicity: The median lethal dose (LD50) for mice and rabbits was 5.0 g/kg and 5.8 g/kg, respectively (administered via high-rate intravenous infusion). The toxicity was attributed to phosphate overload caused by drug hydrolysis. [1]
|
| References | |
| Additional Infomation |
β-D-fructose-1,6-diphosphate is a D-fructose-1,6-diphosphate with a β-configuration at the terminal carbon atom. It is a mouse metabolite functionally related to β-D-fructose. It is the conjugate acid of β-D-fructose-1,6-diphosphate (4-). Fructose-1,6-diphosphate is present in or produced by Escherichia coli (K12 strain, MG1655 strain). See also: trisodium fructose phosphate (note moved to). Mechanism of action: Fructose phosphate bypasses the rate-limiting step of glycolysis, increases ATP production, and reduces lactate accumulation during ischemia. It also scavenge reactive oxygen species (ROS) and inhibits the release of pro-inflammatory cytokines. [1]
- Indications: Primarily used for ischemic heart disease, stroke, and other diseases involving tissue hypoxia. [1] |
| Molecular Formula |
C6H14O12P2
|
|---|---|
| Molecular Weight |
340.1157
|
| Exact Mass |
339.996
|
| CAS # |
488-69-7
|
| Related CAS # |
Fosfructose trisodium;38099-82-0;Fosfructose-13C6 tetrasodium hydrate
|
| PubChem CID |
10267
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
2.1±0.1 g/cm3
|
| Boiling Point |
722.6±70.0 °C at 760 mmHg
|
| Flash Point |
390.8±35.7 °C
|
| Vapour Pressure |
0.0±5.3 mmHg at 25°C
|
| Index of Refraction |
1.626
|
| LogP |
0.49
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
20
|
| Complexity |
428
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
P(=O)(O[H])(O[H])OC([H])([H])[C@@]1([C@]([H])([C@@]([H])([C@@]([H])(C([H])([H])OP(=O)(O[H])O[H])O1)O[H])O[H])O[H]
|
| InChi Key |
RNBGYGVWRKECFJ-ARQDHWQXSA-N
|
| InChi Code |
InChI=1S/C6H14O12P2/c7-4-3(1-16-19(10,11)12)18-6(9,5(4)8)2-17-20(13,14)15/h3-5,7-9H,1-2H2,(H2,10,11,12)(H2,13,14,15)/t3-,4-,5+,6-/m1/s1
|
| Chemical Name |
[(2R,3S,4S,5R)-2,3,4-trihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]methyl dihydrogen phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9401 mL | 14.7007 mL | 29.4014 mL | |
| 5 mM | 0.5880 mL | 2.9401 mL | 5.8803 mL | |
| 10 mM | 0.2940 mL | 1.4701 mL | 2.9401 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
